---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-006046"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2022-04-27T23:59:59+00:00"
generated_at: "2026-06-26T04:10:40.635150+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx appoints Debra Yu, MD to Board of Directors

## Summary
- Dr. Yu appointed effective April 25, 2022 as Class II director; term expires at 2023 annual meeting.
- Recommended by largest shareholder Perceptive Advisors and senior management.
- Currently President and Chief Strategy Officer of LianBio; over 30 years healthcare industry experience.
- Previously held senior positions at Pfizer, Labrador Advisors, and two life science VC firms.
- Eligible for compensation under Company's Non-Employee Director Compensation Program.

## SEC filing metadata
- accession: 0001558370-22-006046
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2022-04-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837022006046/0001558370-22-006046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837022006046/mgtx-20220425x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-006046
- JSON: https://secwatch.observer/filing/0001558370-22-006046.json
- Plain text: https://secwatch.observer/filing/0001558370-22-006046.txt

## Key facts
- Executive change
  Debra Yu was appointed as Class II director at MeiraGTx Holdings plc.
  - Action: appointed
  - Role: Class II director
  source text: On April 25, 2022, the Board of Directors (the “Board”) of MeiraGTx Holdings plc (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Debra Yu, M.D. to the Board as a Class II director, effective immediately, with a term that expires at the Company’s 2023 annual meeting of shareholders and until her successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000155837022006046/0001558370-22-006046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.